Stock Detail
PROGENICS PHARMACEUTICALS INC
Sector: Biotechnology
Latest Quote @ Wed May 5 18:19:36 (15 min delayed)
| $3.85 |
$4.75 |
$3.91 |
-0.11 |
-2.74% |
|
Last Day's Data
| $4.02 |
$4.16 |
$0.00 |
0.00% |
0.00 |
$4.17 |
| $4.11 |
$4.00 |
211,164.00 |
205.12M |
332,756.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 4.22 |
4.12 |
4.06 |
3.96 |
3.90 |
Stock Profile
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. It offers products for the areas of symptom management and supportive care, and the treatment of HIV infection and cancer. The company's methylnaltrexone is designed to reverse the side effects of opioid pain medications while maintaining pain relief and also for the management of post-operative bowel dysfunction caused by endogenous, or naturally occurring, opioids. The company is developing viral-entry inhibitors in the area of HIV infection, including PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5; PRO 542, a genetically engineered molecule designed to neutralize HIV by preventing it from attaching to the CD4 receptor on the surface of immune system cells; ProVax for the prevention of HIV infection or as a therapeutic treatment for HIV-positive individuals. The company, in collaboration with Cytogen Corporation, is developing immunotherapies for prostate cancer, including a human monoclonal antibody directed against prostate-specific membrane antigen, a protein found on the surface of prostate cancer cells. It is also developing vaccines designed to stimulate an immune response to PSMA. The company is also developing a cancer vaccine, GMK, which is in phase 3 clinical trials for the treatment of malignant melanoma. Progenics Pharmaceuticals has agreement with Wyeth Pharmaceuticals for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. The company was founded by Paul J. Maddon. Progenics Pharmaceuticals was incorporated in 1986 and is based in Tarrytown, New York.
